I
218.57
-6.93 (-3.07%)
| Penutupan Terdahulu | 225.50 |
| Buka | 225.69 |
| Jumlah Dagangan | 423,401 |
| Purata Dagangan (3B) | 980,883 |
| Modal Pasaran | 15,386,421,248 |
| Harga / Pendapatan (P/E TTM) | 62.99 |
| Harga / Pendapatan (P/E Ke hadapan) | 36.76 |
| Harga / Jualan (P/S) | 6.11 |
| Harga / Buku (P/B) | 10.70 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 7 May 2026 |
| Margin Keuntungan | 18.29% |
| Margin Operasi (TTM) | 15.61% |
| EPS Cair (TTM) | 5.54 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 28.80% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | -31.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 131.40% |
| Nisbah Semasa (MRQ) | 4.47 |
| Aliran Tunai Operasi (OCF TTM) | 406.50 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 84.25 M |
| Pulangan Atas Aset (ROA TTM) | 6.94% |
| Pulangan Atas Ekuiti (ROE TTM) | 37.92% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Medical Devices (US) | Bercampur | Menurun |
| Medical Devices (Global) | Bercampur | Menurun | |
| Stok | Insulet Corporation | Menurun | Menaik |
AISkor Stockmoo
1.1
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 4.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -2.5 |
| Purata | 1.13 |
|
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide. |
|
| Sektor | Healthcare |
| Industri | Medical Devices |
| Gaya Pelaburan | Mid Growth |
| % Dimiliki oleh Orang Dalam | 0.29% |
| % Dimiliki oleh Institusi | 102.56% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 435.00 (Canaccord Genuity, 99.02%) | Beli |
| Median | 340.00 (55.56%) | |
| Rendah | 274.00 (Barclays, 25.36%) | Jual |
| Purata | 344.42 (57.58%) | |
| Jumlah | 11 Beli, 1 Jual | |
| Harga Purata @ Panggilan | 251.62 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Citigroup | 11 Mar 2026 | 338.00 (54.64%) | Beli | 238.82 |
| 19 Feb 2026 | 345.00 (57.84%) | Beli | 249.10 | |
| Bernstein | 19 Feb 2026 | 330.00 (50.98%) | Beli | 249.10 |
| 09 Jan 2026 | 380.00 (73.86%) | Beli | 289.04 | |
| Canaccord Genuity | 19 Feb 2026 | 435.00 (99.02%) | Beli | 249.10 |
| Evercore ISI Group | 19 Feb 2026 | 340.00 (55.56%) | Beli | 249.10 |
| Goldman Sachs | 19 Feb 2026 | 326.00 (49.15%) | Beli | 249.10 |
| JP Morgan | 19 Feb 2026 | 340.00 (55.56%) | Beli | 249.10 |
| Leerink Partners | 19 Feb 2026 | 360.00 (64.71%) | Beli | 249.10 |
| Oppenheimer | 19 Feb 2026 | 300.00 (37.26%) | Beli | 249.10 |
| Truist Securities | 19 Feb 2026 | 360.00 (64.71%) | Beli | 249.10 |
| BTIG | 18 Feb 2026 | 380.00 (73.86%) | Beli | 258.07 |
| Stifel | 04 Feb 2026 | 350.00 (60.13%) | Beli | 251.24 |
| Barclays | 12 Jan 2026 | 274.00 (25.36%) | Jual | 278.55 |
| Papar semua | ||||
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 05 Feb 2026 | Pengumuman | Insulet Launches Omnipod® 5 and Omnipod Discover™ in the Middle East to Transform Diabetes Care |
| 09 Jan 2026 | Pengumuman | Insulet to Announce Fourth Quarter and Full Year 2025 Financial Results on February 18, 2026 |
| 06 Jan 2026 | Pengumuman | Insulet Redefines Diabetes at CES with "Liveable Technology" — A New Frontier in Human-Centered Connected Health |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |